Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels

Clinical Genetics

Volumn 61, Issue 3, 2002, Pages 176-184

  Larson, I A ^b   Ordovas, J M ^a   Barnard, J R ^c   Hoffmann, M M ^d   Feussner, G ^b   Lamon Fava, S ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apolipoprotein A I; Apolipoproteins; Haplotype; Lipids; Lipoproteins; Polymorphism

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; QUANTITATIVE TRAIT; SEX DIFFERENCE;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUANTITATIVE TRAIT, HERITABLE;

PROTOZOA;

EID: 0036524153     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.610302.x     Document Type: Article

References (66)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dunbar TR. High density lipoproteins as a protective factor against coronary heart disease. The Framingham Heart Study. Am J Med 1977: 62: 707-714.
2. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart Study. High-density lipoproteins as a protective factor against heart disease: a prospective case-control study Lancet 1977: i: 965-968.
3. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991: 325: 373-381.
4. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary artery disease. N Engl J Med 1983: 309: 385-389.
5. Genest J, Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson P et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992: 19: 792-802.
6. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB, Jr. Plasma apolipoprotein A, absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Atherosclerosis 1982: 2: 16-26.
7. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffee D, et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med 1982: 306: 1513-1519.
8. Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS, Heaton W, et al. Familial apolipoprotein A-I and C-III deficiency, variant II. J Lipid Res 1985: 26: 1089-1101.
9. Oram JF, Johnson CT, Brown TA. Interaction of high density lipoprotein with its receptor on cultured fibroblasts and macrophages. J Biol Chem 1987: 262: 2405-2410.
10. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam MYL, Brewer C, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet 1999: 22: 316-318.
11. Fielding CJ, Shore VG, Fielding PE. A protein co-factor of lecithin: cholesteryl acyltransferase. Biochem Biophys Res Commun 1972: 46: 1493-1498.
12. Haffner SM, Applebaum-Bowden D, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, et al. Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II, and D, and lecithin cholesterol acyltransferase. Arteriosclerosis 1985: 5: 169-177.
13. Berg A, Fery I, Keul J. Apolipoprotein profile in healthy males and its relation to maximum aerobic capacity. Clin Chimica Acta 1986: 161: 165-171.
14. Hartung GH, Reeves RS, Foreyt JP, Patsch W, Gotto AM. Effect of alcohol intake and exercise on plasma high density lipoprotein cholesterol subfractions and apolipoprotein A-I in women. Am J Cardiol 1986: 58: 148-151.
15. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994: 35: 871-882.
16. Kuusi T, Kesaniemi YA, Vuoristo M, Miettinen TA, Koskenvuo M. Inheritance of high density lipoprotein lipase and hepatic lipase activity. Arteriosclerosis 1987: 4: 421-425.
17. Moll PP, Michel VV, Weidman WH, Kottke BA. Genetic determination of plasma apolipoprotein A-I in a population based sample. Am J Hum Genet 1989: 44: 24-139.
18. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci USA 1983: 80: 6147-6151.
19. Karathanasis SK. Apolipoprotein multigene family tandem organization of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci USA 1985: 82: 6374-6378.
20. Cheung P, Chan L. Nucleotide sequence of cloned cDNA of human apolipoprotein A-I. Nucl Acids Res 1983: 11: 3703-3715.
21. Cheung P, Kao F-T, Law ML, Jones C, Puck TT, Chan L. Localization of the structural gene for human apolipoprotein A-I on the long arm of human chromosome 11. Proc Natl Acad Sci USA 1984: 81: 508-511.
22. Humphries SE. DNA polimorphism of the apolipoprotein genes - their use in the investigation of the genetic component of hyperlipidemia and atherosclerosis. Atheroclerosis 1988: 72: 89-108.
23. Lusis AJ. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res 1988: 29: 397-429.
24. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, Jowett N, et al. DNA polymorphism in the apo-A-I-C-III gene cluster: association with hypertriglyceridaemia. J Clin Invest 1985: 76: 1090-1095.
25. Funke H, Klug J, Frossard P, Kowalski J, Reckwerth A, Assmann G. Detection of a new Msp I restriction fragment length polymorphism in the apolipoprotein A-I gene. J Clin Chem Clin Biochem 1987: 25: 131-134.
26. Wile DB, Barbir M, Gallagher J, Myant NB, Ritchie CD, Thompson GR, et al. Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration. Atherosclerosis 1989: 78: 9-18.
27. Ordovas JM, Civeira F, Genest J, Jr, Craig S, Robbins AH, Meade T, Pocovi M, et al. Restriction fragment length polymorphisms of the apolipoprotein AI, CIII, AIV gene locus. Relationships with lipids, apolipoproteins and premature coronary artery disease. Atherosclerosis 1991: 87: 75-86.
28. Jeenah M, Kessling A, Millers N, Humphries S. G to A Substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990: 7: 233-241.
29. Pagani F, Sidoli A, Giudici GA, Baenghi L, Vergani C, Barralle FE. Human apolipoprotein A-I gene promoter polymporphism: association with hyperalphalipoproteinemia. J Lipid Res 1990: 31: 1371-1377.
30. Wang XL, Badenhop R, Humphrey K, Wilcken DEL. C to T and G to A transitions are responsible for loss of MspI restriction site in the 5′-region of the human apolipoprotein AI gene. Hum Genet 1995: 95: 473-475.
31. Sigurdsson G, Jr, Gudnason V, Sigurdsson G, Humphries SE. Interaction between a polymorphism of the apo A-I promoter region and smoking determines plasma levels of HDL and apo A-I. Arteriosclerosis Thrombosis 1992: 12: 1017-1022.
32. Minnich A, DeLangavant G, Lavigne J, Roederer G, Lussier-Cacan S, Davignon J. A G→A substitution at position -75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels. Arterioscler-Thromb-Vasc-Biol 1995: 15: 1740-1745.
33. Meng Q-H, Pajukanta P, Valsta L, Aro A, Pietinen P, Tikkanen MJ. Influence of apolipoprotein A-I promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med 1997: 241: 373-378.
34. Paul-Hayase H, Rosseneu M, Robinson D, Van Bervliet JP, Deslypere JP, Humphries SE. Polymorphisms in the apoprotein (apo) A I-C-III-A-IV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Human Genet 1992: 88: 439-446.
35. Xu C-F, Angelico F, Ben MD, Humphries SE. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls. Genetic Epidemiol 1990: 10: 113-122.
36. Talmud PJ, Ye S, Humphries SE. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study. Genet Epidemiol 1994: 11: 265-280.
37. Saha N, Tay JS, Low PS, Basair J, Hong S. Five restriction fragment length polymorphisms of the APOA1-C3 gene and their influence on lipids and apolipoproteins in healthy Chinese. Hum Hered 1995: 45: 303-310.
38. Wang XL, Badenhop R, Humphrey KE, Wilcken DEL. New MspI polymorphism at +83bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol 1996: 13: 1-10.
39. Kamboh MI, Aston CE, Nestlerode CM, McAllister AE, Hamman RF. Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Atherosclerosis 1996: 127: 255-262.
40. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polimorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994: 35: 1292-1296.
41. Lopez-Miranda J, Ordovas JM, Espino A, Marin C, Salas J, Lopez-Segura F, Jimenez-Pereperez J, et al. Influence of mutation in human apolipoprotein A-I gene promoter on plasma LDL cholesterol response to dietary fat. Lancet 1994: 343: 1246-1249.
42. Akita H, Chiba H, Tsuji M, Hui SP, Takahashi Y, Matsuno K, Kobayashi K, et al. Evaluation of G-to-A substitution in the apolipoprotein A-I gene promoter as a determinant of high-density lipoprotein cholesterol level in subjects with and without cholesteryl ester transfer protein deficiency. Hum-Genet 1995: 96: 521-526.
43. Wang XL, Liu S-X, McCredie RM, Wilcken DEL. Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996: 98: 372-377.
44. Civeira F, Pocovi M, Cenarro A, Garces C, Ordovas JM. Adenine for Guanine substitution -78 base pairs 5′?to the apolipoprotein (APO) A-I gene: relation with high density lipoprotein cholesterol and APO A-I concentrations. Clin Genet 1993: 44: 307-312.
45. Carmena-Ramon RF, Ordovas JM, Ascaso JF, Real J, Priego MA, Carmena R. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia. Atherosclerosis 1998: 139: 107-113.
46. Juo SH, Wyszynski DF, Beaty TH, Huang HY, Bailey-Wilson JE. Mild association between the G/A polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. Am J Med Genet 1999: 82: 235 241.
47. Reguero JR, Cubero GI, Batalla A, Alvarez V, Hevia S, Cortina A, Coto E, et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary heart disease. Cardiology 1998: 90: 231-235.
48. Pulkkinen A, Viitanen L, Kareinen A, Lehto S, Laasko M. MspI polymorphism at +83bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease. Diabetes Care 2000: 23: 791-795.
49. Barnard RJ. Effects of lifestyle intervention on serum lipids. Arch Intern Med 1991: 151: 1489-1394.
50. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972: 18: 499-502.
51. Contois JH, McNamara J, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1995: 42: 507-514.
52. Contois JH, McNamara J, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1995: 42: 515-523.
53. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis K, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988: 239: 487-491.
54. Mata P, Lopez-Miranda J, Pocovi M, Alonso R, Lahoz C, Marin C, Garces C, et al. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998: 137: 367-376.
55. Larson IA, Ordovas JM, DeLuca Carl Barnard JR, Feussner G, Schaefer EJ. Association of apolipoprotein (apo) E genotype with plasma apo E levels. Atherosclerosis 2000: 148: 327-335.
56. Seishima M, Bisgaier CL, Davies SL, Glickman RM. Regulation of hepatic apolipoprotein synthesis in 17 α-ethinyl estradiol-treated rat. J Lipid Res 1991: 32: 941-951.
57. Lamon-Fava S, Ordovas JM, Schaefer EJ. Estrogen increases apolipoprotein (apo) A-I secretion in Hep G2 cells by modulating transcription of the apo A-I gene promoter. Arterioscler Thromb Vasc Biol 1999: 19: 2960-2965.
58. Danek GM, Valenti M, Baralle FE, Romano M. The A/G polymorphism in the -78 position of the apolipoprotein A-I promoter does not have a direct effect on transcriptional efficiency. Biochim Biophys Acta 1998: 1398: 67-74.
59. Matsunaga A, Sasaki J, Mori T, Moriyama K, Nishi K, Hidaka K, et al. Apolipoprotein A-I gene promoter polymorphism in patients with coronary heart disease and healthy controls. Nutr Metab Cardiovasc Dis 1995: 5: 269-275.
60. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and prediposition to atheroclerosis. Atherosclerosis 1993: 100: 157-169.
61. Kessling AM, Horsthempke B, Humphries SE. A study of DNA polymorphism around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals. Clin Genet 1985: 28: 296-306.
62. Wick U, Witt E, Engel W. Restriction fragment length polymorphisms at the apoprotein genes AI, Ciii, and B-100 and in the 5′?flanking region of the insulin gene as possible markers of coronary heart disease. Clin Genet 1995: 47: 184-190.
63. Lopez-Miranda J, Jansen S, Ordovas JM, Salas J, Marin C, Castro P, Ostos M, et al. Influence of the SstI polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. Am J Clin Nutr 1997: 66: 97-103.
64. Dallinga-Thie GM, Bu XD, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996: 37: 136-147.
65. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu XD, Lusis AJ, de Bruin T, et al. Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Invest 1997: 99: 953-961.
66. Schemer R, Walsch A, Eisenberg S, Breslow JL, Razin A. Tissue-specific methylation patterns and expression of the human apolipoprotein AI gene. J Biol Chem 1990: 265: 1010-1015.